OncoPrecision
New York
About OncoPrecision
OncoPrecision has reengineered cancer drug discovery by integrating high-throughput patient-derived biology with AI/ML to develop antibody-based therapies (ADCs and bispecifics) with dramatically higher odds of clinical success. Their platform has demonstrated clinical translation with >80% accuracy, unlocking an opportunity to bridge the gap of poor preclinical models that currently lead to a ~5% success rate in oncology drug development. The company is a spin-out of Dr. Gastón Soria’s Synthetic Lethality Lab, which led multi-year oncology collaborations with GSK and uncovered numerous novel therapeutic targets.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $4.2M
- Funding stage: Seed
- Last round: Convertible Note (Jun 2024)
- Website: oncoprecision.bio
- Phone: [email protected]
Industries & Categories
Biotechnology, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/oncoprecision-90166 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.